MedX Board of Directors names Naman Demaghlatrous as President and Chief Executive Officer
MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed as the Company’s President and Chief Executive Officer, effective immediately. The Company wishes to thank Sylvain Desjeans for his service and looks forward to continuing to work with him as he remains a director of MedX.
With more than 20 years of health-care and pharmaceutical industry experience, Mr. Demaghlatrous has served in senior roles with medical and pharma companies in Europe and North America. He joined MedX in 2021 as Managing Director, Europe, Middle East and Africa Operations, and has been focused on developing and expanding the Company’s global market opportunities, and establishing distribution partnerships and adoption in Europe and North America of the MedX Dermsecure® platform and related technology.
“Naman brings extensive knowledge of, and experience in, the global medical technology market,” said Ken McKay, Chairman of the MedX Board of Directors. “His knowledge and experience in the European and North American marketplace will be a valuable asset in developing and expanding the Company’s growth plans in North America and internationally.”
“I would like to thank Ken and the Board of Directors for entrusting me with the responsibility of taking MedX to the next level,” said Naman Demaghlatrous. “Globalizing MedX’s offering now that we have a proven methodology of pilot project to commercial contract is that next step. Penetrating new verticals, strengthening the team, while continuing to leverage our market access, training and education as well as our regulatory resources will both expand our footprint and accelerate our revenue growth.”
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. Teledermatology is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments.
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Contacts
Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547